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Abstract
Background
Cancer and Diabetes Mellitus (DM) are leading causes of death worldwide and the prevalence
of both is escalating. People with co-morbid cancer and DM have increased morbidity and
premature mortality compared with cancer patients with no DM. The reasons for this are likely
to be multifaceted but will include the impact of hypo/hyperglycaemia and diabetes therapies
on cancer treatment and disease progression. A useful step toward addressing this disparity
in treatment outcomes is to establish the impact of cancer treatment on diabetes control.
Aim
The aim of this review is to identify and analyse current evidence reporting glycaemic control
(HbA1c) during and after cancer treatment.
Methods
Systematic searches of published quantitative research relating to comorbid cancer and
type 2 diabetes mellitus were conducted using databases, including Medline, Embase, Psy-
chINFO, CINAHL and Web of Science (February 2017). Full text publications were eligible
for inclusion if they: were quantitative, published in English language, investigated the
effects of cancer treatment on glycaemic control, reported HbA1c (%/mmols/mol) and
included adult populations with diabetes. Means, standard deviations and sample sizes
were extracted from each paper; missing standard deviations were imputed. The completed
datasets were analysed using a random effects model. A mixed-effects analysis was under-
taken to calculate mean HbA1c (%/mmols/mol) change over three time periods compared
to baseline.
Results
The available literature exploring glycaemic control post-diagnosis was mixed. There was
increased risk of poor glycaemic control during this time if studies of surgical treatment for
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gastric cancer are excluded, with significant differences between baseline and 12 months
(p < 0.001) and baseline and 24 months (p = 0.002).
Conclusion
We found some evidence to support the contention that glycaemic control during and/or
after non-surgical cancer treatment is worsened, and the reasons are not well defined in
individual studies. Future studies should consider the reasons why this is the case.
Introduction
Incidence of diabetes mellitus (DM) continues to grow worldwide with 415 million estimated
cases in 2015 and figures are predicted to reach 642 million by 2040 [1]. Current estimates in
the United Kingdom suggest approximately 6% of the population has DM if both diagnosed
and undiagnosed cases are included [2]. There is growing evidence that for individuals with
DM, the risk of developing cancer significantly increases when compared to a non-diabetic
population [3–5]. This is particularly the case for liver, pancreatic, colon/rectum, breast and
bladder cancers [4]. For example, a threefold increase in the risk of developing colorectal can-
cer has been described in Type 2 DM (T2DM) populations [6].
Studies investigating consequences of cancer treatment on people with DM report worse
outcomes when compared to non-diabetic counterparts. Consequences include: increased
mortality [7,8], higher infection rates [9,10], higher hospitalisation rates [10], worse physical
function [11] and poorer prognosis [12,9]. Potential reasons for these poorer outcomes
include: prioritising cancer treatments over DM self-management activities [11,13]; increased
prevalence of and/or under recognition of hyperglycaemia [14]; and clinicians lacking skills in
managing both these complex conditions [14,15]. Sub-optimal DM management during can-
cer care can result in worsened glycaemic control [13]. This has been associated with lower
overall survival [11,16] and may be explained, to some extent, by increased deaths from cardio-
vascular disease [17] and obesity.
Formal guidance on managing patients with comorbid cancer and DM is limited despite a
number of epidemiological studies identifying an increased risk of developing cancer in people
with T2DM [18,19] and potential interactions between treatments for these two diseases [20].
Likewise little is known about the short-term impact of cancer treatment/care on glycaemic
control. One paper found that adherence to glucose lowering drugs decreased in patients fol-
lowing cancer diagnosis [21]. To improve outcomes for patients with both cancer and DM,
health professionals need a greater understanding of the impact cancer treatment has on gly-
caemic control and concomitant DM self-management activities [11,13]. Consequently, this
review was undertaken to answer the following question:
• Does glycaemic control worsen during treatment for cancer in people with T2DM?
Methods
To answer the questions outlined above, we undertook a systematic review and meta-analysis
of published quantitative studies investigating glycaemic control in patients with comorbid
cancer and T2DM. We used HbA1c levels as an indication of glycaemic control. The recom-
mended levels should be individually determined according to age, body weight, concomitant
complications and diabetes duration. Most adults benefit from HbA1c 53 mmols/mol (7%)
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and a clinically relevant difference is considered to be change in HbA1c of 6mmols/mol,
(0.5%) [22,23].
Search strategy
We developed a broad search strategy (Table 1) to increase sensitivity. Adding further search
terms resulted in key papers not being identified. The following databases were searched: Med-
line (1975 to February week 1, 2017), Embase (1975 to February week 1, 2017), PsychINFO
(1975 to February week 1, 2017), CINAHL (1975 to February week 1, 2017), and Web of Sci-
ence (1975 to February week 1, 2017). The search was limited to studies published after 1975,
when glycated haemoglobin (HbA1c) plasma testing was introduced as a measure of glycaemic
control. EC screened titles and abstracts of identified papers. Potentially eligible papers were
reviewed independently by EC and JA.
Eligibility criteria. Studies were included in the review if they:
• reported quantitative findings from randomised controlled trials, observational, cohort, lon-
gitudinal or cross sectional studies, and case note reviews
• were published in English language
• were full text studies
• investigated glycaemic control of T2DM during and up to five years after completing cancer
treatment
• reported HbA1c levels
• included participants 18 years
• described blood glucose and DM complications
Studies were excluded in the review if they:
• included people with pancreatic cancer due to the higher proportion of pancreatic cancer
patients having diabetes and glucose intolerance [24]
• investigated effects of cancer treatment on glycaemic control of Type 1 DM, where type 1
DM share a lesser number of concordant predictors with cancer then T2DM
• reported qualitative findings only
Table 1. Search terms.
Type 2 Diabetes Mellitus Cancer
OR OR
• type 2 diabetes
• glyc?emic control
AND • Cancer
• malignancy
• neoplasm
• melanoma
• h?ematologic malignancy
• lung cancer
• GI disorder/digestive system
• urinary tract cancer
• gyn?ecologic cancer
• breast cancer
• colorectal cancer
• prostate cancer
• brain cancer
• kidneys cancer
• liver cancer
• HbA1c
• blood glucose
• hyperglyc?emia
• Diabetes
https://doi.org/10.1371/journal.pone.0176941.t001
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Data extraction and quality appraisal
In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [25], data on outcomes relating to glycaemic control in patients with
comorbid cancer and T2DM were extracted systematically. We developed standardised forms,
and study data were extracted by SP. Methodological study quality was assessed using the
Effective Public Health Practice Project (EPHPP) Quality Assessment Tool for quantitative
studies [26]. Studies were independently reviewed by two researchers (SP and JA) and dis-
agreements were resolved through discussion. Studies were judged to be low quality if they
had a small sample size, did not describe the study sample, did not describe the study time
frame, did not justify the outcome measures used, failed to control for confounding variables
or did not fully explain statistical analyses performed. Moderate to high-quality papers met
some or all of these criteria. Low-quality papers were not excluded, but results are given less
emphasis in the discussion. Tables summarising key findings were created.
Meta-analysis
We were interested in measuring HbA1c (%/mmols/mol) change over time post baseline
(diagnosis and/or cancer treatment initiation). The time points of interest were selected based
on available data as follows; baseline (T0), one year post-baseline (T1), two years post-baseline
(T2).
Of the papers eligible for inclusion the following data were extracted: mean, standard devia-
tion (SD) and number of participants. Missing SDs were imputed using metagear etd software
package in R. This uses the coefficient of variation from all complete cases to calculate missing
values [27,28]. Datasets with imputed values were then analysed using a random effects model
within the metafor software package [29]. This model does not make an inference based on
just the studies analysed, but sees them as a random sample of studies from a larger population
of studies that could or have been done; thus it allows for estimation of heterogeneity and
inference to a broader population of studies.
To test if there was a statistically significant difference between the three time periods the
means, SDs and variance estimates were extracted from each of the analyses; and a mixed-
effects model analysis undertaken in metafor using the time period (baseline, one year follow-
ing, two years following) as the moderator variable. The three pooled estimates were them-
selves entered into a fixed-effects regression model with the time point as the moderating
factor. This allowed for calculation of both change over these time periods compared to the
baseline, and the amount of heterogeneity explained by the model; as well as confidence inter-
vals and p-values. Full data and code are shown in S1 Appendix.
Results
The literature search generated 6,886 potential papers of which 775 were duplicates. Following
title and abstract review, 6,067 were excluded (Fig 1). Of 44 papers read in full, 36 were
excluded and eight papers were selected for review (for further details on excluded papers,
please refer to Fig 1).
Study characteristics
Details of the eight included studies are provided in Table 2. Five were undertaken in the
United States of America [30–34], one in South Korea [35], one in Taiwan [36] and one in
China [37].
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All eight studies employed a retrospective review of case notes and/or medical information
design focused on a convenience sample of patients with cancer and pre-existing T2DM. Of
these, five studies used a within group comparison using the same participants who had
T2DM before and after receiving cancer treatment [30,31,33,35,37]. Three studies compared
cancer patients with pre-existing T2DM to cancer patients with no history of T2DM, before
and after cancer treatment [32,34,36]. A total of 6,433 people participated in the included stud-
ies and sample sizes were diverse, ranging from 29 [33] to 4,474 participants [34]. Participants’
mean age ranged from 59.0 years [37] to 75.0 years [33]. Based on diagnostic groups studied;
three studies included male-only participants [32–34], one study included female-only partici-
pants [31] and four studies included both male and female participants [30,35,36,37].
All studies assessed the impact of cancer diagnosis and/or cancer treatment on T2DM out-
come, however timing of assessments varied between studies. Whilst for two studies [32,36]
time frames were unclear, for the remaining studies the time interval from first to last data col-
lection points ranged from 12 [35,37] to 84 months [30]. Most studies focused on one cancer
type, with the exception of one study which included patients with either breast, colon or pros-
tate cancer [30]. Of those studies focusing on one cancer type, three included men with pros-
tate cancer [32–34], one included people with myeloma [36], one included women with breast
cancer [31] and two studies included people with gastric cancer [35,37].
Measurement of glycaemic control. All selected studies routinely assessed HbA1c
(%/mmols/mol) as a long term determinant of glycaemic control. Mean percentage HbA1c
level (and mmol/mol) at different time points are described in Table 3 and Table 4.
Fig 1. Data retrieval and assessment.
https://doi.org/10.1371/journal.pone.0176941.g001
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In the study by Haidar and colleages [33], between five and eight HbA1c levels were
recorded throughout a 24 month period (mean HbA1c = 9.3%, 78 mmol/mol).
Four studies also recorded fasting blood glucose (FBG) [32,33,35,37], two studies recorded
serum glucose [35,36], one study recorded serum insulin and homeostasis model assessment-
estimated insulin resistance (HOMA-IR) [35]; one study recorded administered insulin dose
[33]; and one study recorded BMI and C-peptide levels [37]. Adherence and changes to diabetes
medication were reported in three studies [31,34], as well as information on diabetes-related
complications assessed by occurrence of neuropathy, nephropathy and retinopathy [36].
Table 3. Mean percentage (and mmol/mol) HbA1c across study time points.
Time point
Author, Year
(Sample size)
Diagnosis Treatment Pre-base-
line
Baseline* (Diagnosis and/
or treatment start)
Post-baseline (in months)
3 6 12* 24* 36 60
An et al. 2013 Early gastric cancer, Surgery
STG B Ia (n = 36) 7.2 (55) 6.8
(51)
7.0
(53)
7.1
(54)
STG B IIb (n = 16) 7.3 (56) 6.9
(52)
7.1
(54)
7.1
(54)
Total Gc (n = 12) 7.1 (54) 6.5
(48)
6.5
(48)
6.5
(48)
Calip et al. 2015
(n = 399)
Stage I and II breast cancer, Surgery,
chemo-therapy, endocrine therapy
7.0 (53) 7.3 (56) 7.4
(57)
7.4
(57)
7.3
(56)
Chou et al. 2012
(n = 34)
Myeloma Chemotherapy 7.1 (54)
Derweesh et al.
2007 (n = 77)
Prostate ADT* (surgical or medical) 7.1 (54) 7.2
(55)
Haidar et al. 2007
(n = 29)
Prostate ADT 6.3 (45)
Keating et al. 2014
(n = 2,105)
Prostate ADT 7.2 (55) 7.4
(57)
7.4
(57)
Liu et al. 2015 Gastric cancer, Surgery
A (n = 30) 9.5 (1.0) 5.4
(0.6)
4.6
(0.4)
B (n = 21) 9.1 (1.1) 8.8
(0.7)
9.2
(1.2)
C (n = 25) 8.9 (0.9) 7.1
(0.8)
7.8
(0.5)
D (n = 17) 9.6 (1.0) 5.8
(0.5)
4.8
(0.3)
* Time points selected for comparison in meta-analysis
a Subtotal gastrectomy with gastroduodenostomy
b Subtotal gastrectomy with gastrojejunostomy
c Total gastrectomy
* Androgen Deprivation Therapy
https://doi.org/10.1371/journal.pone.0176941.t003
Table 4. Median percent (%) HbA1c across study time points.
Time points -24 pre diagnosis to -6
months
-6 months to
diagnosis (0)
Diagnosis (0) to 6
months
6 months to 12
months
12 months to 24
months
24 months to 60
months
Bayliss et al. 2011
(n = 553)
7.9 (63) 7.6 (60) 7.7 (61) 7.8 (62) 7.9 (63) 7.8 (62)
https://doi.org/10.1371/journal.pone.0176941.t004
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Quality assessment
Most studies were either of moderate [30,31,35] or weak quality [32,33,36,37] and one was
judged to be of strong quality [34]. Detailed evaluation of each study using the EPHPP criteria
is shown in Table 5.
Generally, papers described as being of weak quality had small sample sizes from a single
clinical setting [33], failed to describe if data were missing and/or how this was dealt with
[32,33,36,37], excluded cases lacking complete data without sufficiently describing details of
the process [33] and did not appropriately describe or deal with confounding variables
[32,33,36,37]. Papers described as being of moderate quality failed to provide sufficient detail
on the patients’ cancer such as type and stage [30,35], details of how patients were selected and
why [35], how missing data was dealt with [30], or did not appropriately deal with confound-
ing variables [31].
Glycaemic control. Four studies found no significant difference in HbA1c levels for dia-
betic patients before and after cancer treatment initiation [30,35] or diabetic patients before
and after cancer treatment initiation compared to non-diabetic controls [32,36]. Two studies
reported an increase in HbA1c after androgen deprivation therapy (ADT) was initiated
[33,34] and one study described raised HbA1c levels following diagnosis and treatment (not
specified) for breast cancer [31]. One study in gastric cancer showed mixed results according
to type of surgical procedure and/or BMI, however the study design was judged to be weak
[37].
Of the four studies measuring FBG, two described a significant increases in FBG at 24
months [33] and 60 months [32] after receiving a course of ADT. However both were evalu-
ated as weak quality studies and reported results for time bands rather than specified time
points. For people with gastric cancer one study reported a significant decrease in FBG within
12 months following gastrectomy [35] whilst the other showed reduction only for those with a
high BMI who underwent a total gastrectomy and modified Roux-en-y anastomosis and those
with normal BMI who underwent a total gastrectomy and standard Roux-en-y anastomosis
[37].
In three studies measuring insulin resistance, one study described a significantly lower
resistance to insulin post-gastrectomy [35] and two studies reported increased insulin require-
ments after patients commenced ADT [33,34].
Risks and side effects. Adherence to diabetic medications from the time of cancer diag-
nosis was described in three studies. For current DM medication users, patients reported they
either ceased taking DM medications [35], or reduced DM medications use after their cancer
Table 5. Quality assessment of included studies.
Study Selection
bias
Study
design
Confounds Data collection
methods
Withdrawals and drop
outs
Statistical analyses
suitable
Global
rating
An et al (2013) Moderate Weak Strong Moderate Strong Yes Moderate
Bayliss et al.
(201)
Moderate Moderate Strong Moderate Weak Yes Moderate
Calip et al. 2015 Moderate Moderate Weak Moderate Moderate Yes Moderate
Chou et al. 2012 Weak Moderate Weak Strong Weak Yes Weak
Derweesh et al.
2007
Weak Weak Weak Moderate Weak Yes Weak
Haidar et al. 2007 Weak Weak Weak Weak Weak Yes Weak
Keating et al.
2014
Moderate Moderate Strong Strong Moderate Yes Strong
Liu et al. 2015 Weak Moderate Weak Strong Weak Yes Weak
https://doi.org/10.1371/journal.pone.0176941.t005
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diagnosis [31,35]. The proportion of patients achieving recommended HbA1c levels decreased
following worsened adherence to DM medication after being diagnosed with breast cancer
[31]. Following diagnosis, one study reported that prostate cancer patients were prescribed
new DM medication, or changed their current DM medication to a new class once commenc-
ing ADT [34]. Drug classes included metformin, sulfonylureas, other oral drugs and insulins.
Women with breast cancer identified as being non-adherent with oral T2DM medication
were more likely to be taking4 cardiovascular disease medications then adherent users [31].
Meta-analysis
Six of the seven papers included in the systematic review were included in the meta-analysis.
The paper by Haidar and colleagues [33] was excluded as it only reported median and range,
the data was too heterogeneous, the study time points did not match those of interest and no
response was received from the corresponding author in attempt to clarify these points. The
paper by Bayliss and colleagues [30] was excluded as the data were too heterogeneous and the
study time points did not match those of interest.
We ran three meta-analyses for time points at which data across studies could be clustered
together for comparison (see Table 3). Time 0 (T0) (baseline from diagnosis/treatment initia-
tion) included data from six studies [31,32,34,35,36,37]. Time 1 (T1) (12 months post baseline)
included data from four studies [31,34,35,37]. And time 2 (T2) (24 months post baseline)
included data from two studies [31,34].
We compared the mean % (mmol/mol) HbA1c levels and SDs. Although all studies pro-
vided mean scores, SDs were missing from some and so we calculated SDs from standard
errors where provided [31,34]. For studies which provided means and ranges [32,35,36] SDs
were imputed using metagear [38].
Results are presented as forest plots (Figs 2–5). At baseline mean HbA1c was 7.94% (63
mmol/mol; 95% CI 7.32, 8.56) and subject to high levels of heterogeneity (Q = 359.11 df = 10,
Fig 2. Forest plot of studies considering mean HbA1c levels (%) at time of cancer diagnosis and
treatment initiation.
https://doi.org/10.1371/journal.pone.0176941.g002
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p< .0001, I2 98.91%). At T1 mean HbA1c was 6.86% (52 mmol/mol; 95% CI 5.93, 7.80), and
subject to high levels of heterogeneity (Q = 2151.52, df = 8, p< .0001, I2 99.65%). At T2 the
mean was 7.37% (57 mmol/mol; 95% CI 7.29, 7.45), this was less heterogeneous but only
included two studies (Q = 0.66, df = 1, p = 0.42, I2 0%).
Fig 3. Forest plot of studies considering mean HbA1c levels (%) at 12 months post time of cancer
diagnosis and treatment initiation.
https://doi.org/10.1371/journal.pone.0176941.g003
Fig 4. Forest plot of studies considering mean HbA1c levels (%) at 24 months post time of cancer
diagnosis and treatment initiation.
https://doi.org/10.1371/journal.pone.0176941.g004
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The analysis was repeated excluding the study by An and colleagues [35] and Liu and col-
leagues [37] because of the effects of gastric cancer surgery on weight loss. At baseline the
mean HbA1c was 7.21% (55 mmol/mol; 95% CI 7.13, 7.29) and subject to moderate levels of
heterogeneity (Q = 5.20 df = 3, p = 0.16, I2 41.38%). At T1 the mean HbA1c was 7.39% (57
mmol/mol; 95% CI 7.32, 7.46) and subject to low levels of heterogeneity but only included two
studies (Q = 0.14, df = 1, p =<0.71, I2 0%). At T2 the mean HbA1c was 7.37% (56 mmol/mol;
95% CI 7.29, 7.45), again with low levels of heterogeneity but only including two studies
(Q = 0.66, df = 1, p = 0.42, I2 0%). There was a significant difference between T0 and T1 esti-
mates (p< 0.001) and T0 and T2 estimates (p = 0.002).
Discussion
Results from the meta-analysis demonstrate deterioration in HbA1c levels at 24 months post-
cancer diagnosis and treatment initiation. When limiting the analysis to exclude studies with
populations receiving gastric surgery, HbA1c levels increase at both 12 and 24 months in com-
parison to baseline.
All studies included routinely assessed HbA1c as a long term determinant of blood glucose
levels. Four studies found no significant difference in HbA1c levels before and after cancer
treatment [30,32,35,36], three reported an increase in HbA1c levels following cancer diagnosis
and treatment [31,33,34] and one reported mixed results depending on participants BMI and
type of surgical procedure undergone [37]. This discrepancy may be explained by differences
in BMI resulting from the specific cancer diagnosis and/or its corresponding treatment. For
example, the first line treatment for gastric cancer is radical surgery which removes some or all
of the stomach and limits food intake [35,37]. An alternative explanation for this discrepancy
might be that clinically significant changes in glycaemic control necessitated adjustment of
diabetes therapy however this was not reflected in changes in HbA1C.
Differences in cancer type and cancer treatment across studies may also explain inconsis-
tencies in the results between the studies. For example, the three studies which highlighted
adverse effects on glycaemic control included populations that may have received hormone
therapy as a part of their cancer care [31,33,34]. Two studies described a significant increase
in FBG at up to 24 [33] and 60 months [32] after receiving a course of ADT, suggesting an
increase in insulin resistance. On the other hand, two studies [35,37] reported a significant
Fig 5. Forest plot of collapsed studies considering HbA1c levels at baseline and two-year estimates.
https://doi.org/10.1371/journal.pone.0176941.g005
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decrease in FBG within 12 months following gastrectomy further suggesting that cancer type
and corresponding treatment will have differing effects on glycaemic control. Chemotherapy
drug regimens vary according to cancer type/stage however none of the studies provided infor-
mation on this. Thus it is possible that differences in glycaemic control arise from different
treatment regimens being compared. Likewise many patients are administered steroids as part
of an anti-emetic regimen however due to the lack of information provided by the included
studies it is not possible to assess the impact of this on glycaemic control. Further research is
required to investigate this in more detail.
Considerable differences between studies may explain the lack of consistency in the associa-
tion between HbA1c levels and initiation of cancer treatment. For example, the timing of
HbA1c recordings relative to the timing of their cancer diagnosis varied greatly across the
studies. The study by Chou and colleagues [36], which was rated as being of weak quality, only
measured HbA1c at baseline, therefore there was no comparison. Whilst Derweesh and col-
leagues [32], also judged as being of weak quality, assessed HbA1c on more than one occasion
(baseline and 60 months post-diagnosis or treatment initiation), it is possible patients had
either fully recovered by the second assessment or had sufficient time to adapt to these two
concurrent illnesses. Generally there was variation between studies in relation to: cancer diag-
nosis (type, stage, severity), cancer treatment (chemotherapy, endocrine therapy, radiotherapy,
surgery, ADT), competing comorbidities (obesity and cardiovascular disease), attention to
potential confounders (duration of DM, treatment history, supportive medications) and
inconsistencies in inclusion and exclusion criteria, dealing with missing data and use of a con-
trol group for comparison.
Poor outcomes such as hyperglycaemia have been reported in patients with comorbid can-
cer and diabetes [14] but it should be noted that there is little available data to date. For
patients with comorbid cancer and diabetes, the adverse outcomes highlighted in this review
include higher mortality rates [36], consistent with findings in several studies [7,8,11,16] and
poor adherence to DM medications [31,34,35] as reported by Hershey and colleagues [11].
Poorer adherence to diabetic medications post-cancer diagnosis was described in three
studies and patients reported they either ceased taking DM medications [35], or reduced DM
medications use after diagnosis [31,35]; and this supports findings from the study by Zanders
and colleagues [21]. An explanation for this may be that little attention is paid to glycaemic
control by cancer health professionals and/or poorer self-management by the patients them-
selves when also burdened with the added responsibilities and strains associated with other
competing chronic conditions [30] including cancer self-management [13], however evidence
to support this is extremely limited. It is also possible that there is a lack of integrated care and
competing care priorities but again, evidence to support this is limited. It would be useful to
know how this group of people assess and decide between competing care priorities. Being
able to differentiate between modifiable and non-modifiable factors at both the cancer and
T2DM level may help health professionals to identify how best to support and intervene with
this group of people.
Limitations and recommendations
The findings of this meta-analysis are limited by the small number of studies reporting on the
impact of cancer treatment on glycaemic control and adverse outcome in people with T2DM.
This is further compounded by methodological issues and inconsistencies identified in the
seven included studies. All used a retrospective design incorporating routinely collected data
which varied in terms of data completeness and also time points at which data collection
occurred relative to cancer treatment. As the studies were observational there was no suitable
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comparison group and it is possible that glycaemic control may worsen in participants’ with-
out a cancer diagnosis over the 12 to 24 month period [39]. Generally it is not clear whether
studies included all patients who passed through the system, or excluded those with missing
information. Inconsistencies in key clinical variables made comparisons between studies diffi-
cult. A prospective study design may have better resolved some of these issues. Finally we ini-
tially intended to evaluate whether DM complications are greater in people with T2DM who
receive cancer treatment, however this was not possible due to the limited evidence available.
Concluding remarks and implications for research
This meta-analysis found that following treatment for cancer (and particularly ADT) there is a
small statistically significant increase in HbA1c in people with pre-existing T2D when gastric
surgery cases are removed. Whilst this increase was not clinically meaningful, results should be
treated with caution due the lack of high quality evidence available for review. The limited
research conducted evaluating glycaemic control in cancer patients with T2DM means it is not
possible to judge potentially serious outcomes as a result of treatment interactions in this pop-
ulation. Understanding such potential interactions and outcomes could help inform decisions
made by health care professionals regarding treatments and care pathways. Future research
is required to investigate glycaemic control during cancer treatment and what happens to
HbA1c levels and DM complications during steroids and cytotoxic and antiemetic regimes.
The research may help inform best care for patients with comorbid cancer and DM.
Supporting information
S1 Appendix. Full data and code (metafor).
(PDF)
S1 Table. PRISMA check list.
(PDF)
Author Contributions
Conceptualization: JA KW SP.
Data curation: EP SP.
Formal analysis: EP SP.
Funding acquisition: JA KW.
Investigation: JA EC SP.
Methodology: JA KW SP EC EP.
Project administration: JA.
Supervision: JA KW SP.
Validation: EP JA SP.
Visualization: JA SP KW EP.
Writing – original draft: SP JA KW EP.
Writing – review & editing: SP JA KW EP EC.
Glycaemic control in people with diabetes mellitus during and after cancer treatment: A systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0176941 May 3, 2017 15 / 17
References
1. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Feder-
ation. 2015. Available from: http://www.diabetesatlas.org. Accessed 15 July 2016.
2. Gatineau M, Hancock C, Holman N, Outhwaite H, Oldridge L, Christie A, et al. Adult obesity and type 2
diabetes. Oxford: Public Health England; 2014
3. Jee SH, Kim HJ, Lee J. Obesity, insulin resistance and cancer risk. Yonsei Med J. 2005; 46: 449–455.
https://doi.org/10.3349/ymj.2005.46.4.449 PMID: 16127767
4. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and can-
cer: a consensus report. CA: Cancer J Clin. 2010; 60: 207–221.
5. Yang X, Ko GT, So WY, Ma RC, Yu LW, Kong AP, et al. Associations of hyperglycemia and insulin
usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010; 59:
1254–1260. https://doi.org/10.2337/db09-1371 PMID: 20185812
6. Nagel JM, Goke B. Colorectal carcinoma screening in patients with type 2 diabetes mellitus. Z Gastro-
enterol. 2006; 44: 1153–1165. https://doi.org/10.1055/s-2006-927132 PMID: 17115358
7. Attili VS, Bapsy PP, Dadhich HK, Batra U, Lokanatha D, Babu KG. Impact of diabetes on cancer che-
motherapy outcome: a retrospective analysis. Int J Diabetes Dev Ctries. 2007; 27: 122–128.
8. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in
cancer patients with preexisting diabetes mellitus. A systematic review and meta-analysis. JAMA.
2008; 300: 2754–2764. https://doi.org/10.1001/jama.2008.824 PMID: 19088353
9. Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectr. 2006;
19: 157–162.
10. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and
outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol. 2009; 27: 2170–
2176. https://doi.org/10.1200/JCO.2008.17.5935 PMID: 19307509
11. Hershey DS, Given B, Given C, Corser W, von Eye A. Predictors of diabetes self-management in older
adults receiving chemotherapy. Cancer Nurs. 2014; 37: 97–105. https://doi.org/10.1097/NCC.
0b013e3182888b14 PMID: 23519039
12. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment
and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2: 48–53. https://doi.org/10.1038/ncponc0062
PMID: 16264856
13. Hershey DS, Given B, Given C, Von Eye A, You M. Diabetes and cancer: impact on health-related qual-
ity of life. Oncol Nurs Forum. 2012; 39: 449–457. https://doi.org/10.1188/12.ONF.449-457 PMID:
22940509
14. Morganstein DL, Tan S, Gore M, Feher MD. Prevalence of diabetes in patients admitted to a cancer
hospital. Br J Diabetes Vasc Dis. 2012; 12: 178–180.
15. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;
29: 725–731. PMID: 16505540
16. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, Bacon L, Rivera D, Urzua L, et al. Impact of diabetes
and hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res; 2012; 1–8.
17. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation
therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448–4455. https://doi.org/10.1200/JCO.2006.06.
2497 PMID: 16983113
18. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients
with type 2 diabetes who use sulphonylureas or insulin. Diabetes Care. 2006; 29: 254–258. PMID:
16443869
19. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 dia-
betes. Diabetologia. 2009; 52: 1766–1777. https://doi.org/10.1007/s00125-009-1440-6 PMID:
19572116
20. Tinetti ME, Bogardus ST, Agostini, JV. Potential pitfalls of disease-specific guidelines for patients with
multiple conditions. N Engl J Med. 2004; 351: 2870–2874. https://doi.org/10.1056/NEJMsb042458
PMID: 15625341
21. Zanders MM, Haak HR, van Herk-Sukel MP, van de Poll-Franse LV, Johnson JA. Impact of cancer on
adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia. 2015; 58:
951–960. https://doi.org/10.1007/s00125-015-3497-8 PMID: 25638246
22. Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, et al. The A1C and ABCD of glycaemia
management in type 2 diabetes: a physician’s personalized approach. Diabetes Metab Res Rev. 2010;
26: 239–244. https://doi.org/10.1002/dmrr.1092 PMID: 20503255
Glycaemic control in people with diabetes mellitus during and after cancer treatment: A systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0176941 May 3, 2017 16 / 17
23. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale E, et al. Intensive glycemic control
and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes
trials. Diabetes Care. 2009; 32: 187–192. https://doi.org/10.2337/dc08-9026 PMID: 19092168
24. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer.
Mol Cancer. 2003; 2:4. Available: http://molecular-cancer.biomedcentral.com/articles/10.1186/1476-
4598-2-4. https://doi.org/10.1186/1476-4598-2-4 PMID: 12556242
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-
analysis: the PRISMA statement. Ann Intern Med. 2009; 151: 264–270. PMID: 19622511
26. Jackson N, Waters E. Criteria for the systematic review of health promotion and public health interven-
tions. Health Promot Int. 2005; 20: 367–374. https://doi.org/10.1093/heapro/dai022 PMID: 16169885
27. Lajeunesse M. Bias and correction for the log response ratio in ecological meta-analysis. Ecol. 2015;
96: 2056–2063.
28. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical
Computing. Vienna, Austria. 2016. Available: https://cran.cnr.berkeley.edu/doc/manuals/r-release/
fullrefman.pdf
29. Viechtbauer W. Package: Metafor. Meta-analysis package for R. 2016. Available at website https://
cran.r-project.org/web/packages/metafor/metafor.pdf.
30. Bayliss EA, Blatchford PJ, Newcomer SR, Steiner JF, Fairclough DL. The effect of incident cancer,
depression and pulmonary disease exacerbations on type 2 diabetes control. J Gen Intern Med. 2011;
26: 575–581. https://doi.org/10.1007/s11606-010-1600-x PMID: 21203859
31. Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM. Adherence to oral diabe-
tes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol
Drug Saf. 2015; 24: 75–85. https://doi.org/10.1002/pds.3660 PMID: 24923811
32. Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, et al. Risk of new-onset
diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing andro-
gen-deprivation therapy for prostate cancer. BJU Int. 2007; 100: 1060–1065. https://doi.org/10.1111/j.
1464-410X.2007.07184.x PMID: 17868420
33. Haidar A, Yassin A, Saad F, Shabsigh R. Effects of androgen deprivation on glycaemic control and on
cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging
Male. 2007; 10: 189–196. https://doi.org/10.1080/13685530701653538 PMID: 18033628
34. Keating NL, Liu PH, O’Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes
control among diabetic men with prostate cancer. Eur Urol. 2014; 65: 816–824. https://doi.org/10.1016/
j.eururo.2013.02.023 PMID: 23453420
35. An JY, Kim YM, Yun MA, Jeon BH, Noh SH. Improvement of type 2 diabetes mellitus after gastric can-
cer surgery: Short-term outcome analysis after gastrectomy. World J Gastroenterol. 2013; 19: 9410–
9417. https://doi.org/10.3748/wjg.v19.i48.9410 PMID: 24409070
36. Chou YS, Yang CF, Chen HS, Yang SH, Yu YB, Hong YC, et al. Pre-existing diabetes mellitus in
patients with multiple myeloma. Eur J Haematol. 2012; 89: 320–327. https://doi.org/10.1111/j.1600-
0609.2012.01828.x PMID: 22758386
37. Liu T, Xie G, Tian Q. Radical gastrectomy combined with modified bypass surgery for gastric cancer
patients with type 2 diabetes. Cell Biochem Biophys. 2015; 72: 839–844. https://doi.org/10.1007/
s12013-015-0546-3 PMID: 25677989
38. Lajeunesse MJ. Metagear: comprehensive research synthesis tools for systematic reviews and meta-
anlysis. 2017. Available: https://cran.r-project.org/web/packages/metagear/index.html
39. Best JD, Drury PL, Davis TM, Taskinen MR, Kesaniemi YA, Scott R, et al. Glycemic control over 5
years in 4,900 people with type 2 diabetes. Real-world diabetes therapy in a clinical trial cohort. Diabe-
tes Care. 2012; 35: 1166–1170.
Glycaemic control in people with diabetes mellitus during and after cancer treatment: A systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0176941 May 3, 2017 17 / 17
